The gastric modifier esomeprazole did not affect the bioavailability and tolerability of CS-7017 in an open-label, phase I, two-way crossover clinical study in healthy subjects

Authors
Category Primary study
JournalEuropean Journal of Cancer, Supplement
Year 2010
This article has no abstract
Epistemonikos ID: 756d51d0495e1bea7f9d337f1f1a4d0dd6e78cfe
First added on: Mar 01, 2025